KRAS and neoplasm: The expansion cohort included 28 patients with biliary cancer (60 mg BID dose group), 31 patients with KRAS-mutant colorectal cancer (6 patients in the 60 mg BID dose group and 25 in the 45 mg BID dose group), and 15 patients with BRAF-mutant colorectal cancer (45 mg BID dose group).The predominant tumour type was colorectal (57%); 54% of patients had an ECOG performance status of 0.